Frequently Asked Questions
Higher drug development activities for developing and launching several new drugs are the streptococcus infection market opportunities for growth in the market.
Asia-Pacific dominates the streptococcus infection market due to the increased prevalence of bacterial infections and increasing investment in healthcare infrastructure.
Rising adoption of antibiotics & prevalence of streptococcus diseases are the growth drivers of the streptococcus infection market.
Bacterial type, diagnosis, treatment, distribution channel, and end-use are the factors on which the streptococcus infection market research is based.
Major companies in the streptococcus infection market are AstraZeneca (U.K.), Lilly (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Novartis AG (Switzerland), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), Merck & Co., Inc. (U.S.), Pfizer Inc. (U.S.), GSK plc (U.K.), Hikma Pharmaceuticals PLC (U.K.), Cipla Inc. (India), Lupin (India)
